MIRA Pharmaceuticals, Inc. (MIRA)
| Market Cap | 17.55M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -11.24M |
| Shares Out | 16.56M |
| EPS (ttm) | -0.57 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 376,291 |
| Open | 1.020 |
| Previous Close | 1.000 |
| Day's Range | 1.000 - 1.090 |
| 52-Week Range | 0.510 - 5.010 |
| Beta | n/a |
| Analysts | Strong Buy |
| Price Target | 14.00 (+1,220.76%) |
| Earnings Date | Nov 12, 2024 |
About MIRA
MIRA Pharmaceuticals, Inc. operates as a pre-clinical-stage pharmaceutical development company with two neuroscience programs targeting a range of neurologic and neuropsychiatric disorders. The company holds exclusive U.S., Canadian, and Mexican rights for Ketamir-2, a patent pending oral ketamine analog under investigation to deliver ultra-rapid antidepressant effects for individuals battling treatment-resistant depression, major depressive disorder with suicidal ideation, and post-traumatic stress disorder. In addition, its oral pharmaceutica... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 2 analysts, the average rating for MIRA stock is "Strong Buy." The 12-month stock price forecast is $14.0, which is an increase of 1,220.76% from the latest price.
News
MIRA Pharmaceuticals Submits IND for Ketamir-2 to FDA, Marking a Significant Milestone in the Company's Pipeline Development
MIAMI, FL / ACCESSWIRE / December 19, 2024 / MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA), a preclinical-stage pharmaceutical company focused on developing therapies for neurological and neuropsychiatric ...
MIRA Pharmaceuticals Validates Ketamir-2's Safety Profile With No Adverse Findings, Paving the Way for IND Submission by Year-End
Strong Safety Profile Validated Across Studies, Setting the Stage for Clinical Trials in Neuropathic Pain MIAMI, FL / ACCESSWIRE / December 10, 2024 / MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA), a precl...
MIRA Reveals Innovative Phase I/IIa Protocol Design and Selection of Clinical Trial Site
Backed by a Strong Balance Sheet, MIRA Accelerates Toward Becoming a Clinical-Stage Company and Advancing Breakthroughs in Pain and Depression Treatment MIAMI, FL / ACCESSWIRE / November 20, 2024 / MI...
MIRA Pharmaceuticals' Ketamir-2 Shows 60% Greater Efficacy Than FDA-Approved Gabapentin in Reversing Chemotherapy-Induced Neuropathic Pain
Promising Preclinical Results Position Ketamir-2 as a Potential Breakthrough Therapy That Surpasses Current Treatments, With Results to Be Presented at the Pain Therapeutics Summit in Boston MIAMI, FL...
MIRA Pharmaceuticals Announces Ketamir-2 Outperforms Current FDA-Approved Neuropathic Pain Treatments, Gabapentin and Pregabalin, in Preclinical Study
MIAMI, FL / ACCESSWIRE / October 21, 2024 / MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA), a leading pre-clinical-stage pharmaceutical development company, is excited to announce that its novel oral ketami...
MIRA Pharmaceuticals Announces New Preclinical Data for Ketamir-2 to Be Presented at the 18th Annual Pain Therapeutics Summit in Boston on October 28-29, 2024
Conference presentation delivers preclinical results demonstrating Ketamir-2 achieves 100% reversal of neuropathic pain MIAMI, FL / ACCESSWIRE / September 27, 2024 / MIRA Pharmaceuticals, Inc. (NASDAQ...
MIRA Pharmaceuticals Advances Ketamir-2 Development Following Phase 1 Design Completion, Focusing on Early Clinical Efficacy Demonstration for Neuropathic Pain in 2025
MIAMI, FL / ACCESSWIRE / September 18, 2024 / MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA), a preclinical-stage pharmaceutical company focused on developing innovative therapies for neurologic and neurops...
MIRA Pharmaceuticals Designates Neuropathic Pain as Primary Indication for Ketamir-2 and Submits Pre-IND Meeting Request to FDA
MIAMI, FL / ACCESSWIRE / September 11, 2024 / MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA), a preclinical-stage pharmaceutical company focused on developing innovative therapies for neurologic and neurops...
MIRA Pharmaceuticals Achieves 100% Reversal of Neuropathic Pain With Oral Ketamir-2 in Breakthrough Study
Study Highlights Superior Efficacy of Ketamir-2 Over Oral Ketamine, Achieving Full Normalization of Pain Thresholds MIAMI, FL / ACCESSWIRE / August 26, 2024 / MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA),...
MIRA Pharmaceuticals Showcases Significant Progress and Announces Final Phase of Regulatory Work as It Prepares for IND Submission by Year-End
MIAMI, FL / ACCESSWIRE / August 19, 2024 / MIRA Pharmaceuticals Inc. (NASDAQ:MIRA) "MIRA" or the "Company"), a leading pre-clinical-stage pharmaceutical company, is pleased to provide a comprehensive ...
MIRA Pharmaceuticals Unveils Ketamir-2's Principal Metabolite: Nor-Ketamir - a Longer-Acting, Brain Penetrating and Selective Compound Acting on the NMDA PCP Receptor
This breakthrough in bioavailability and formulation showcases the potential for advanced, at home neurological treatments. MIAMI, FL / ACCESSWIRE / August 12, 2024 / MIRA Pharmaceuticals, Inc. (NASDA...
MIRA Pharmaceuticals Announces Positive Discovery of Ketamir-2's Selective NMDA Binding Mechanism of Action
Latest positive preclinical data provides another step in the path to potential IND submission this year for novel ketamine analog MIAMI, FL / ACCESSWIRE / July 25, 2024 / MIRA Pharmaceuticals, Inc. (...
S&P 500 Gains 1%; MIRA Pharmaceuticals Shares Spike Higher
U.S. stocks traded higher toward the end of trading, with the NASDAQ Composite gaining around 300 points on Monday.
MIRA Pharmaceuticals Reveals Preclinical Success: Ketamir-2 Optimized for Brain Delivery, Avoiding Ketamine's Drug Resistance
New findings highlight potential advantages of MIRA's novel oral ketamine analog for treating neurological and neuropsychiatric disorders MIAMI, FL / ACCESSWIRE / July 22, 2024 / MIRA Pharmaceuticals,...
Mira Pharmaceuticals Announces Promising Results for MIRA-55 in Multiple Preclinical Tests Compared to THC
Testing confirms MIRA's preliminary beliefs regarding potential treatment for neurological and neuropsychiatric disorders MIAMI, FL / ACCESSWIRE / July 15, 2024 / MIRA Pharmaceuticals, Inc. (Nasdaq:MI...
MIRA Pharmaceuticals Announces Ketamir-2 Shows Promising Safety Profile in Comparison to Traditional Ketamine In Preclinical Testing
New preclinical studies suggest that, unlike traditional ketamine, MIRA's oral ketamine analog Ketamir-2 does not induce hyper-locomotor activity, indicative of psychotic symptoms, offering the potent...
MIRA Announces Positive Test Results
The company announced that it achieved positive preclinical study results for Ketamir-2, its Novel Oral ketamine Analog.
Mira Pharmaceuticals Announces Positive Preclinical Study Results For Its Novel Oral ketamine Analog, Ketamir-2, Paving the Way for IND Submission Later This Year
The positive results from this preclinical study underscore Ketamir-2's potential as a superior alternative to traditional ketamine Unlike ketamine, which requires intravenous or intranasal administra...
Mira Pharmaceuticals Announces DEA Rules MIRA-55, a Novel Oral Pharmaceutical Marijuana Analog, Is Not Classified as a Controlled Substance
Ruling removes potential complications for manufacturing, pre-clinical development, IND submission, clinical development, and ultimately commercialization. MIAMI , May 29, 2024 /PRNewswire/ -- MIRA Ph...
MIRA Pharmaceuticals in Discussions with Memorial Sloan Kettering to Collaborate on Preclinical Cancer Pain Model Utilizing The Company's Novel Oral Ketamine Analog
Ketamir-2, the Company's novel oral ketamine analog in development, aims to provide a safe and effective alternative for managing cancer pain and associated depression MIAMI , May 21, 2024 /PRNewswire...
Mira Pharmaceuticals Advances Preclinical Trials Towards an IND Submission This Year for Ketamir-2, a Differentiated Oral Ketamine Analog
Investigative studies are underway testing Ketamir-2 as the potential first at home ketamine analog treatment for PTSD, depression, and neuropathic pain, including cancer pain MIAMI , May 20, 2024 /P...
Mira Pharmaceuticals Announces Encouraging Preclinical Results Advancing Ketamir-2 Towards Potential Year-End IND Submission
Ketamir-2 is a potential treatment for certain major mental health disorders impacting millions of people in the U.S. MIAMI , April 2, 2024 /PRNewswire/ -- MIRA Pharmaceuticals, Inc. (NASDAQ: MIRA) ("...
MIRA Pharmaceuticals Welcomes Dr. Itzchak Angel, former Head of Pharmacology at Synthelabo, as Chief Scientific Advisor
A seasoned pharmaceutical industry executive with over 40 years at the forefront of innovation, including at Synthelabo (acquired by Sanofi-Aventis), Dr. Angel aims to propel MIRA Pharmaceuticals' mis...
MIRA Pharmaceuticals Provides Corporate Update
Announces Research Collaboration with Pharmaseed to Conduct Pre-Clinical Studies on the Use of Ketamir for Patients with Major Depressive Disorder (MDD) and Post-Traumatic Stress Disorder (PTSD) Studi...
MIRA Pharmaceuticals Releases Breakthrough Data from Artificial Intelligence Simulations
AI Simulation on MIRA1a Showcases Significant Potential Advantages Over Plant-Based Medical Marijuana Related to Anxiety, Appetite and Cognition BALTIMORE , Dec. 4, 2023 /PRNewswire/ -- MIRA Pharmaceu...